Biota Of Australia Reaps Large Profits From Relenza Antiviral Royalties
This article was originally published in PharmAsia News
Australia's Biota, the biotech that came up with the Relenza (zanamivir) antiviral marketed globally by U.K.-based GlaxoSmithKline, saw a doubling in royalties the past year. The near future looks even brighter for Biota, which reaped just over U.S.$31.5 million in profits, based primarily on the Relenza royalties. GSK plans by the end of the year to triple production of the drug as a major treatment for the widely expected H1N1 flu pandemic, so Biota anticipates a continuation of large royalties. (Click here for more
You may also be interested in...
Plaintiffs against the prestige, “clinical” skin-care company are targeting anti-aging claims on its Rose Stem Cell Bio-Repair line and statements about hyaluronic acid’s ultra-moisturizing capabilities, used to market its Water Drench range. PTR faces false advertising class actions in California and New York federal courts, and the former case appears to be headed for trial.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
LifeSignals plans to soon launch a biosensor patch to consumers to help them monitor for potential symptoms of COVID-19.